• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Bioactive Products
    Anticancer Compound Library
    A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research
    Catalog No: B91 Anticancer Compound Library
    Screening Details
    Size: 1mg/well * 674 Compounds
    2mg/well * 674 Compounds
    Catalog No. Information
    CFN99001 Gelsemine

    1. Gelsemine has antitumor activity.
    2. Gelsemine has anti-oxidative activity.
    3. Gelsemine has anti-hyperlipidemic activity.
    4. Gelsemine has marked antinociception in inflammatory, neuropathic and bone cancer pains without inducing antinociceptive tolerance.
    CFN99004 Caffeine

    1. Caffeine has anxiolytic-like activity, can have both positive and negative effects on anxiety.
    2. Caffeine inhibits glucose transport by binding at the GLUT1 nucleotide-binding site.
    CFN99007 Caudatin

    1. Caudatin exerts antiproliferative effects on human hepatocellular carcinoma SMMC7721 cells.
    2. Caudatin has anticancer activity, due partly to its inhibition of cell proliferation and induction of apoptosis in cancer cells through caspase activation.
    3. Caudatin exhibits significantly inhibitory activity against HBV DNA replication with IC50 values in the range of 2.82-7.48 μM.
    4. Caudatin inhibits carcinomic human alveolar basal epithelial cell growth and angiogenesis by targeting GSK3β/β-catenin pathway and suppressing VEGF production.
    CFN99010 Pectolinarigenin

    1. Pectolinarigenin exhibits hepatoprotective activity mainly via SOD antioxidant mechanism.
    2. Pectolinarigenin possesses anti-inflammatory activity and that they may inhibit eicosanoid formation in inflammatory lesions.
    CFN99012 Schisandrin A

    1. Schisandrin A has hepatoprotective activity.
    2. Schisantherin A is a potent P-gp inhibitor.
    3. Schisandrin A, as an inhibitor of CYP3A, possesses a clinically beneficial property of altering the disposition of drugs metabolized by CYP3A.
    4. Schisantherin A demonstrates strong and comparable activities to reverse the drug resistance and the intracellular drug accumulation in four mediated multidrug resistance (MDR) cell lines.